Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
about
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4Novel strategies to target the ubiquitin proteasome system in multiple myelomaModulatory effects of bortezomib on host immune cell functionsWhen ubiquitin meets NF-κB: a trove for anti-cancer drug developmentTouch and go: nuclear proteolysis in the regulation of metabolic genes and cancerNovel therapeutic strategies for multiple myelomaDual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaSmall compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myelomaBlocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cellsExpression of GITR Enhances Multiple Myeloma Cell Sensitivity to BortezomibTyrosine phosphorylation allows integration of multiple signaling inputs by IKKβGalectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myelomaInhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemiaA proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradationThe pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoMCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κBTargeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications.A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy.Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.A review of the application of inflammatory biomarkers in epidemiologic cancer research.The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiationMantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraBortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity.The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaBortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.Proteasome inhibitors in cancer therapyProtein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.NF-κB addiction and its role in cancer: 'one size does not fit all'.Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cellsProteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.
P2860
Q24294703-3ECB8199-018D-4351-9F7A-F4DDDD5BAAA6Q26773246-7F26BF56-1FD4-4F92-BF80-777B5B7111E5Q26795618-34D0CC39-6D81-404F-B7FD-46413D55612CQ26827754-9041352E-B2DD-486D-8739-D0E707D6D7EBQ28068146-624F6E96-32CA-4BC3-8F86-4FC00A31C0B2Q28081590-360E282A-65AB-4869-AA77-69FB494DD5F1Q28271286-7C29E494-BFEC-4E33-8058-BF53C82FBC80Q28478936-8552B849-65CF-4AC2-91FE-56268C44D703Q28481321-8CCCCE10-8384-470C-87C8-523B5917F769Q28547243-CA1340E0-ED82-40BC-8804-1142E862CF11Q28660962-68D31539-49C4-4A17-9B8D-14CC5FA3C993Q28742668-5F3AD153-C5A6-4BAE-B242-606E8A129120Q31028788-9CAA973B-548F-4435-90AB-51865457B167Q33407672-EA31F175-1AF5-48BE-8406-E5E3D4B61A71Q33617012-D333EB5A-18BB-42D0-BC72-308A6B6525ABQ33732419-7A5AA5C1-60E9-4B60-A3E3-8C68AC69F688Q33834752-CEF89E8F-8146-40EC-85AD-9A7A3740EA46Q33855223-27490CF8-8854-4899-AEE9-B718D13623F4Q33896749-A031F561-528C-4C60-B039-878EE80281B5Q34038263-B0808D44-89CB-42E7-85E6-0BB9A5D4B896Q34043821-ECB56372-0789-4B81-BF27-2D54198AE2A2Q34044757-6B10865C-629A-4B33-80FB-0EB31BB12DEBQ34048276-23081CC9-FE17-41F4-8A80-8ADCC54918C5Q34135803-5EA4E643-F19C-4333-B807-864846E12404Q34235332-03A0DED0-C504-4C41-B5F7-8269B28E4D57Q34542087-684CD121-633C-42A8-A898-67C49A7B19E5Q34568868-1B945CE3-9DB2-491B-AD32-491FC28EDF4DQ34576976-747183DE-2168-462A-8B09-EB90A0988FC0Q34707136-2C1A9668-B6C2-4888-9A2D-CE71FF6D12DCQ34786865-4F7D9EAA-B97D-4779-8C9C-3DA2BC322766Q34788381-45046433-A087-4F61-8840-1609ED3FDEA9Q34890498-DCED65FC-3468-46B1-80D3-C863D24C1765Q34924231-CFBDBC1A-2A05-4139-AB88-C4553015DE53Q34939959-770603BB-C2CF-4B21-8B2D-351BC976B1A9Q35005510-1085604A-E1B1-45A2-9607-9918FFED63E6Q35054403-41190195-76D2-44C6-9289-BCE3DE2025A8Q35120893-990050D0-75B8-41F6-BBB0-130C2A90557FQ35146262-165835CC-D0AC-4EFF-AB0A-882CCBFAB38BQ35167162-59A0B8B8-A369-4888-8AE3-62CCCBA07EC6Q35408665-44BA9571-EAFE-4870-A53B-2447B6FAC0D3
P2860
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
@en
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
@nl
type
label
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
@en
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
@nl
prefLabel
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
@en
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
@nl
P2093
P2860
P1433
P1476
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
@en
P2093
Constantine Mitsiades
Dharminder Chauhan
Hiroshi Ikeda
Klaus Podar
Nikhil C Munshi
Noopur Raje
Ruben D Carrasco
Teru Hideshima
Yutaka Okawa
P2860
P304
P356
10.1182/BLOOD-2009-01-199604
P407
P577
2009-05-12T00:00:00Z